Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trilakt
- Development stage
- Unknown
- Lead developer
- Vector-BiAlgam
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Trilakt is a liquid probiotic preparation developed by AO Vector-BiAlgam, containing a concentrated complex of five live antagonistic active strains of lactobacilli, including Lactobacillus acidophilus, Lactobacillus casei, and Lactobacillus plantarum. It is designed to restore and maintain the natural balance of intestinal microflora, particularly in cases of intestinal dysbiosis, and to support the host immune system. The mechanism of action involves the colonization of the intestinal mucosa by beneficial bacteria that produce organic acids (such as lactic acid), hydrogen peroxide, and bacteriocins. these metabolites inhibit the growth of pathogenic and opportunistic microorganisms. Trilakt is often utilized as part of a comprehensive probiotic complex alongside Bifidum BAG and Ecoflor to provide a synergistic effect in treating gastrointestinal disorders and recovering from antibiotic therapy.
- Brand names
- TrilaktТрилакт
- Other names
- Trilakt probiotic
Beyond the preview
Go deeper on Trilakt.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trilakt.